Rx Product News

Published Online: Thursday, March 13, 2014
Follow Pharmacy_Times:

Stendra
Marketed by:
Auxilium Pharmaceuticals, Inc 
Indication: Stendra (avanafil) is a phosphodiesterase 5 inhibitor indicated for the treatment of erectile dysfunction. The recommended starting dose is 100 mg. The dose may be increased to a maximum of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once per day. Stendra should be taken as needed approximately 30 minutes before sexual activity.
Dosage Form: Tablets: 50, 100, and 200 mg
For More Information: www.stendra.com



Breo Ellipta
Marketed by:
GlaxoSmithKline and Theravance, Inc
Indication: Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), which received FDA approval in May 2013, is now available to pharmacies throughout the United States. Breo Ellipta is indicated for long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease. The recommended dose is 1 oral inhalation (100 mcg/25 mcg) once daily.
Dosage Form: Inhalation powder (fluticasone furoate/vilanterol): 100 mcg/25 mcg
For More Information: http://phrmcyt.ms/Mzyvep


Gazyva
Marketed by:
Genentech, Inc
Indication: The FDA has approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Gazyva should be diluted and administered as an intravenous (IV) infusion—not as an IV push or bolus. The recommended dose for 6 cycles (28-day cycles) is 100 mg on day 1, cycle 1; 900 mg on day 2, cycle 1; 1000 mg on days 8 and 15 of cycle 1; and 1000 mg on day 1 of cycles 2 through 6.
Dosage Form: Single-use vial: 1000 mg/40 mL (25 mg/mL)
For More Information: www.gazyva.com


Copaxone
Marketed by:
Teva Pharmaceutical Industries Ltd
Indication: The FDA has approved a supplemental new drug application for 3-times-a-week Copaxone (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS). This new formulation will allow patients with relapsing MS to have a less frequent subcutaneous dosing regimen (ie, 3 times per week). Daily Copaxone 20 mg/mL for subcutaneous injection will continue to be available.
Dosage Form: Subcutaneous injection: 20 and 40 mg/mL
For More Information: www.copaxone.com/40-mg-injection

Related Articles
Grocery store chain joins growing list of major companies offering enhanced specialty pharmacy.
The FDA has approved peginterferon beta-1a (Plegridy), a groundbreaking injectable therapy for patients with relapsing forms of multiple sclerosis.
A recent article suggests that comparing 2 or more observations of a patient’s COPD symptoms over time can help clinicians learn why patients lose control of the disease.
Latest Issues
$auto_registration$